A total of 69 persons were investigated for assessment of cell-mediated and humoral immunity to hepatitis B surface antigen (HBsAg). With the recognition of hepatitis B surface antigen (HBsAg, originally designated Australia antigen; 2) as an immunological marker of hepatitis B virus, a better understanding of the natural history and the epidemiology of hepatitis B results from application of more sensitive and specific serologic methods for the detection of HBsAg and anti-HBs (
hepatitis B virus, a better understanding of the natural history and the epidemiology of hepatitis B results from application of more sensitive and specific serologic methods for the detection of HBsAg and anti-HBs (1, 3, 5, 14, 17, 20, 23, 25) . The immunological mechanisms in a spectrum of clinical manifestation of hepatitis B virus infection could be studied by assessing the cellular and humoral immune response to HBsAg. Although the results of recently published work with single patient samples have enhanced our understanding of the immunological mechanisms in hepatitis B, certain disparate results may in part be due to technical differences, to the nature of the antigen used in the assays, to limitation of the patient population studied, to failure of obtaining serial samples, and to lack of simultaneous testing of cellular and humoral immunity (4, 6, 7, 8, 9, 13, 16, 18, 24) . In this study, cell-mediated immune response was measured in vitro by leukocyte migration inhibition by purified and immunochemically characterized HBsAg, and humoral immune response was measured by a sensitive and specific hemagglutination assay for antibody. In the first phase of the investigation, a point study of 20 convalescent hepatitis B patients, 20 asymptomatic HBsAg carriers, and 20 controls was carried out. The findings led to an investigation of sequential specimens from nine patients giving results that appear to define the cellular and humoral immune response to HBsAg during the course of and after hepatitis B virus infection.
MATERIALS AND METHODS
Selection of patients. Three groups were examined in the first stage of our study (Table 1) . Groups A and B each consisted of 20 age-and sex-matched, healthy, adult voluntary blood donors in an excellent state of health. Routine examination of their sera for serum glutamic pyruvic transaminase, Immunoglobin G (IgG), IgA, IgM, and hemolytic complement (C'H50) levels revealed them to be within normal limits established for our clinical laboratory. Subjects in group A were negative for HBsAg and anti-HEs, whereas subjects in group B were consistently positive for HBsAg and negative for anti-HBs over a period of at least 3 months. Group C consisted of patients convalescing from an acute episode of typical hepatitis B who had a loss of HBsAg from their serum during a period of 2 to 12 weeks before their immunological evaluation. A majority of the patients were attending the hepatitis clinic at the San Francisco General Hospital. None of the patients gave a history of transfusion or parenteral exposure to drugs.
Purified HBsAg. Large volumes of ACD plasma of an asymptomatic healthy carrier of subtype adw were derived by plasmapheresis and stored at -20 C until used for purification of HBsAg by zonal ultracentrifugation. The purification was carried out by two successive runs of isopycnic banding in cesium chloride gradients followed by a rate sedimentation separation of the 20-nm particles from the filamentous forms and larger Dane particles. Immunochemical characterization of the purified HBsAg particles devoid of human plasma proteins has been described previously (22) . The purified HBsAg not only consisted of the 20-nm particles of HBsAg, but also lacked the deoxyribonucleic acid (DNA) polymerase activity associated with the core of the Dane particles (11) . The purified HBsAg (20-nm particles at a concentration of 1 mg/ml in saline) was kept frozen in No. tested 20 20 20 HBsAg-positive aThese two samples were negative in counter electrophoresis and hemagglutination inhibition but were positive in radioimmunoassay performed retrospectively.
antigen was diluted so that a 0.1-ml sample contained 30 ,g of HBsAg.
Leukocyte migration inhibition assays. A 40-ml sample of blood was collected with a disposable plastic syringe containing 0.4 ml of phenol-free heparin, and the erythrocytes were allowed to sediment at 37 C. Leukocyte-rich supernatant plasma was aspirated, and the cells were used for (21) . When counterelectrophoresis and hemagglutination inhibition were negative, a solid-phase sandwich radioimmunoassay (15) kit was used for confirmation (AUSRIA, Abbott Laboratories, Chicago Ill.). Tests for antibodies to HBs were carried out by titration of sera with inert indicator erythrocytes coated with purified HBsAg (21) . Titers less than 1:4 were not taken into consideration unless the titer showed a definite rise in a subsequent specimen.
RESULTS
The results of cell-mediated immunity to HBsAg assessed by LMI assay and humoral immune response assessed by antibody titration with HBsAg-coated cells are depicted in Table   1 . Cell-mediated immunity was not demonstrable in any of the 20 controls or in the 20 chronic carriers of HBsAg. However, the LMI was positive in subjects C2, C3, and C6, who were convalescing from hepatitis B. Subject C2 was not available for repeat testing, but the repeat LMI tests in the other two subjects turned negative within a 2-to 3-week period. It was noteworthy that subjects C2 and C3 were negative for HBsAg when tested by hemagglutination inhibition but positive in radioimmunoassay at the time their LMI indexes were 0.69 and 0.52, respectively. The distribution of LMI indexes in each group are graphically presented in Fig. 1 . Three subjects, C l, C7, and C8, showed anti-HBsAg 11 to 12 weeks after conversion to an HBsAg negative test. Repeat LMI tests 3 weeks later on C3 and C6 were negative. Thus, the results in Table 1 indicate the transient nature of LMI and late occurrence of antibodies in a minority of patients in group C. Simultaneous occurrence of anti-HBs and HBsAg or LMI was never observed in any subject.
During the second stage of our study, six patients with hepatitis B were followed up as closely as possible from the time of onset of clinical disease and diagnostic detection of HBsAg at intervals as detailed in Table 2 . Three additional patients, 7, 8, and 9, from the hepatitis clinic were not available for full study; however, their results also were consistent with the fact the LMI test becomes transiently positive 4 to 8 weeks after onset of acute disease, concomitant with clearing of the antigen from the circulation. All patients recovered from the acute epidose of hepatitis without clinical, sero- (4, 9, 16) . Cell-mediated immune response has been demonstrated in normals and patients with previous history of hepatitis B by leukocyte migration inhibition assay by using HBsAgpositive human serum or liver homogenates from HBsAg-positive liver biopsies (7, 13, 24) and by purified antigen (8, 18 
